Header Logo

James Moy

Concepts (199)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Asthma
18
2021
137
2.280
Why?
Antibodies, Viral
6
2022
89
1.450
Why?
Immunoglobulin G
8
2022
129
1.390
Why?
Immunoglobulins, Intravenous
4
2018
16
1.000
Why?
Antibody Formation
2
2022
38
0.990
Why?
Salivary alpha-Amylases
1
2023
1
0.870
Why?
Viral Vaccines
1
2022
4
0.850
Why?
Vaccines
1
2022
13
0.840
Why?
Immunologic Deficiency Syndromes
3
2017
10
0.820
Why?
Agammaglobulinemia
2
2018
2
0.780
Why?
Common Variable Immunodeficiency
2
2018
5
0.780
Why?
Bacterial Infections
3
2018
66
0.740
Why?
Genetic Diseases, X-Linked
1
2018
1
0.620
Why?
Immunoglobulins
1
2017
29
0.590
Why?
Child, Preschool
12
2019
654
0.580
Why?
Immunologic Factors
1
2017
39
0.570
Why?
Immunotherapy
1
2017
66
0.570
Why?
Biomarkers
6
2023
707
0.550
Why?
Fluticasone
4
2019
5
0.530
Why?
Humans
39
2023
29830
0.530
Why?
Child
12
2021
1376
0.490
Why?
Adrenal Cortex Hormones
5
2019
102
0.470
Why?
Glucocorticoids
4
2019
69
0.450
Why?
Precision Medicine
3
2021
26
0.420
Why?
Respiratory Sounds
2
2019
10
0.390
Why?
Bronchodilator Agents
3
2019
14
0.380
Why?
Female
22
2021
16417
0.350
Why?
Adolescent
9
2019
2331
0.350
Why?
Male
21
2021
15858
0.350
Why?
Salmeterol Xinafoate
2
2019
3
0.340
Why?
Adult
13
2021
8731
0.340
Why?
Alendronate
2
2019
9
0.340
Why?
Ibuprofen
2
2021
12
0.330
Why?
NF-kappa B
3
2022
111
0.300
Why?
Young Adult
6
2019
1966
0.290
Why?
Double-Blind Method
9
2021
520
0.290
Why?
Saliva
2
2023
54
0.290
Why?
Middle Aged
10
2021
9953
0.290
Why?
Anti-Asthmatic Agents
4
2018
21
0.280
Why?
Administration, Inhalation
7
2019
26
0.270
Why?
Antibodies, Neutralizing
2
2022
28
0.260
Why?
Eosinophilia
2
2017
47
0.230
Why?
Cockroaches
1
2003
3
0.230
Why?
Respiratory Hypersensitivity
1
2003
5
0.230
Why?
Allergens
1
2003
22
0.230
Why?
Acetaminophen
3
2021
22
0.220
Why?
Nucleocapsid
1
2022
3
0.220
Why?
Neutralization Tests
1
2022
10
0.210
Why?
beta-Glucans
1
2022
26
0.210
Why?
Sputum
2
2019
23
0.200
Why?
Health Personnel
1
2022
115
0.190
Why?
Pandemics
2
2021
237
0.190
Why?
Infant
6
2018
542
0.190
Why?
Lung
2
2019
158
0.180
Why?
Prospective Studies
4
2019
1821
0.180
Why?
Immunity, Innate
1
2021
91
0.180
Why?
Cohort Studies
3
2021
1953
0.180
Why?
Adrenergic beta-2 Receptor Agonists
1
2019
2
0.170
Why?
Education, Medical, Continuing
1
2020
45
0.170
Why?
Hypersensitivity
1
2020
46
0.170
Why?
Tiotropium Bromide
1
2019
2
0.170
Why?
Mometasone Furoate
1
2019
6
0.170
Why?
Receptors, Adrenergic, beta-2
1
2019
5
0.170
Why?
Randomized Controlled Trials as Topic
1
2021
349
0.170
Why?
Vitamin A Deficiency
1
2018
1
0.160
Why?
Vitamin A
1
2018
6
0.160
Why?
Contrast Sensitivity
1
2018
8
0.160
Why?
Eosinophils
1
2019
47
0.160
Why?
Betacoronavirus
1
2020
75
0.160
Why?
Zinc
1
2018
36
0.160
Why?
Longitudinal Studies
1
2022
1462
0.160
Why?
Drug-Related Side Effects and Adverse Reactions
1
2018
32
0.150
Why?
Glutathione
1
2018
32
0.150
Why?
Arginine
1
2018
19
0.150
Why?
Coronavirus Infections
1
2020
86
0.150
Why?
Pneumonia, Viral
1
2020
89
0.150
Why?
Leukotriene Antagonists
1
2016
1
0.140
Why?
Inhalation Exposure
2
2008
6
0.140
Why?
Treatment Outcome
4
2018
3557
0.140
Why?
Sensitivity and Specificity
3
2022
558
0.130
Why?
Postoperative Complications
1
2022
957
0.130
Why?
Azithromycin
1
2015
4
0.130
Why?
Respiratory Tract Infections
1
2015
22
0.130
Why?
Secondary Prevention
1
2015
63
0.130
Why?
Research Design
3
2021
214
0.130
Why?
HIV Infections
1
2022
997
0.130
Why?
Pregnenediones
1
2014
3
0.120
Why?
Vitamins
1
2014
16
0.120
Why?
Cholecalciferol
1
2014
6
0.120
Why?
Vitamin D Deficiency
1
2014
10
0.120
Why?
Recurrence
3
2016
352
0.120
Why?
Cotinine
2
2011
5
0.100
Why?
Anti-Bacterial Agents
1
2015
401
0.100
Why?
Quality of Life
1
2017
676
0.100
Why?
Dose-Response Relationship, Drug
3
2019
455
0.100
Why?
Antibody-Dependent Cell Cytotoxicity
2
2023
28
0.100
Why?
Severity of Illness Index
3
2021
1126
0.100
Why?
Pruritus
1
2011
10
0.100
Why?
Dermatitis, Allergic Contact
1
2011
6
0.100
Why?
Silicones
1
2011
8
0.100
Why?
Peritoneal Dialysis
1
2011
22
0.100
Why?
Catheters, Indwelling
1
2011
26
0.100
Why?
Mexican Americans
1
2011
28
0.090
Why?
Follow-Up Studies
3
2018
1859
0.090
Why?
Smoking
1
2011
194
0.090
Why?
Prevalence
2
2018
494
0.090
Why?
Inflammation
2
2022
348
0.080
Why?
Cross-Over Studies
2
2019
80
0.080
Why?
Aged
3
2018
9633
0.080
Why?
Tobacco Smoke Pollution
1
2008
7
0.080
Why?
Case-Control Studies
2
2021
640
0.080
Why?
Leukocyte Count
2
2019
92
0.080
Why?
Albuterol
2
2018
15
0.070
Why?
Models, Biological
1
2008
348
0.070
Why?
Cross-Sectional Studies
3
2018
970
0.070
Why?
Acetates
1
2005
19
0.060
Why?
Quinolines
1
2005
16
0.060
Why?
Incidence
2
2018
759
0.060
Why?
Pyroglyphidae
1
2003
3
0.060
Why?
Air Pollution, Indoor
1
2003
3
0.060
Why?
Skin Tests
1
2003
14
0.060
Why?
Urban Health
1
2003
23
0.060
Why?
Child Welfare
1
2003
17
0.060
Why?
Cats
1
2003
75
0.060
Why?
Statistics as Topic
1
2003
114
0.060
Why?
Dogs
1
2003
261
0.060
Why?
Sialic Acid Binding Immunoglobulin-like Lectins
1
2023
4
0.050
Why?
Signal Transduction
2
2022
493
0.050
Why?
Hepatitis B Antibodies
1
2022
1
0.050
Why?
Hepatitis B e Antigens
1
2022
1
0.050
Why?
Hepatitis B Surface Antigens
1
2022
9
0.050
Why?
Antibodies
1
2023
66
0.050
Why?
Syk Kinase
1
2022
11
0.050
Why?
Killer Cells, Natural
1
2023
93
0.050
Why?
Respiratory Syncytial Viruses
1
2002
1
0.050
Why?
Lectins, C-Type
1
2022
112
0.050
Why?
Chemokines
1
2002
29
0.050
Why?
Serologic Tests
1
2022
14
0.050
Why?
Clinical Trials, Phase II as Topic
1
2021
29
0.050
Why?
Advisory Committees
1
2021
34
0.050
Why?
Gene Expression Regulation, Neoplastic
1
2002
107
0.050
Why?
Clinical Protocols
1
2021
64
0.050
Why?
Immunization, Passive
1
2021
20
0.050
Why?
Seroepidemiologic Studies
1
2021
20
0.050
Why?
Immunoglobulin M
1
2021
19
0.050
Why?
Immunoglobulin Fc Fragments
1
2021
9
0.050
Why?
Complement Activation
1
2021
14
0.050
Why?
Receptors, Fc
1
2021
12
0.050
Why?
Antibody Specificity
1
2021
54
0.050
Why?
Spike Glycoprotein, Coronavirus
1
2021
17
0.050
Why?
Phagocytosis
1
2021
51
0.050
Why?
Tumor Necrosis Factor-alpha
1
2002
224
0.050
Why?
United States
2
2018
2344
0.050
Why?
Administration, Oral
2
2014
143
0.040
Why?
Education, Distance
1
2020
18
0.040
Why?
Drug Combinations
1
2019
82
0.040
Why?
Proof of Concept Study
1
2019
12
0.040
Why?
Adrenergic beta-Antagonists
1
2019
42
0.040
Why?
Reproducibility of Results
1
2021
802
0.040
Why?
Medication Adherence
1
2019
79
0.040
Why?
Surveys and Questionnaires
1
2003
1186
0.040
Why?
Peak Expiratory Flow Rate
1
2018
1
0.040
Why?
Ornithine
1
2018
3
0.040
Why?
Growth
1
2018
5
0.040
Why?
Analgesics, Non-Narcotic
1
2018
17
0.040
Why?
Tomography, X-Ray Computed
1
2021
778
0.040
Why?
Forced Expiratory Volume
1
2017
9
0.040
Why?
Immunoglobulin E
1
2017
15
0.040
Why?
Chicago
2
2011
867
0.040
Why?
Fever
1
2016
40
0.030
Why?
Neutrophils
1
2017
118
0.030
Why?
Kaplan-Meier Estimate
1
2016
177
0.030
Why?
Phenotype
1
2017
363
0.030
Why?
Drug Resistance, Bacterial
1
2015
52
0.030
Why?
Drug Administration Schedule
1
2015
232
0.030
Why?
Animals
1
2003
4654
0.030
Why?
Treatment Failure
1
2014
161
0.030
Why?
Pain
1
2016
396
0.030
Why?
Disease Progression
1
2015
812
0.030
Why?
Patch Tests
1
2011
2
0.020
Why?
Exanthema
1
2011
16
0.020
Why?
Morbidity
1
2011
63
0.020
Why?
Regression Analysis
1
2011
298
0.020
Why?
Half-Life
1
2009
18
0.020
Why?
Drug Dosage Calculations
1
2009
6
0.020
Why?
Drug Evaluation
1
2009
56
0.020
Why?
Kidney Failure, Chronic
1
2011
158
0.020
Why?
Socioeconomic Factors
1
2008
329
0.020
Why?
Sulfides
1
2005
12
0.020
Why?
Adrenergic beta-Agonists
1
2005
19
0.020
Why?
Cyclopropanes
1
2005
26
0.020
Why?
Placebos
1
2005
81
0.020
Why?
Acetylcysteine
1
2002
11
0.010
Why?
Free Radical Scavengers
1
2002
13
0.010
Why?
Oxidation-Reduction
1
2002
71
0.010
Why?
Tumor Cells, Cultured
1
2002
149
0.010
Why?
Dexamethasone
1
2002
48
0.010
Why?
Antiviral Agents
1
2002
136
0.010
Why?
Lung Neoplasms
1
2002
636
0.010
Why?
Moy's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (199)
Explore
_
Co-Authors (9)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_